Absolute and relative effects answer different questions. Write down the event rate in each arm and the difference between them; everything quotable is derived from those two numbers.
0 likes 14mo
Evidence · Trials · continued
Reading a trial's population section before its results — does this still hold? posts 151–155
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Clear enough that I do not think I have a follow-up, which is unusual.
11 likes 14mo
t.kulkarni, post #74: Agreed, and I will stop repeating the version of this I had been repeating. Go to post
A comparator at less than its maximum licensed dose changes what a head-to-head result means. It does not invalidate the trial; it narrows the claim the trial supports.
Take the reasoning and check the arithmetic; I do not always get it right.
Composite endpoints should be read component by component. A composite driven entirely by its softest component is a different finding from one where the components move together.
That holds under the stated conditions and I have stated them.
0 likes 14mo
This topic was referenced in
- Interim analyses and stopping rules — does this still hold?Evidence › Trials · 34 replies
- Revisiting: Primary endpoint hierarchies and why order mattersEvidence › Trials · 25 replies
Promoted into the documentation commons. The content of this topic is maintained at FLOW — trial digest, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.
This topic was closed 180 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Non-inferiority margins: how they are chosen and how they are abused — a second dataset
Non-inferiority margins: how they are chosen and how they are abused — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Non-inferiority…
|
+32 | 37 | 574 | 5mo |
|
Comparators chosen for regulatory reasons rather than clinical ones
On the subject in the title: Comparators chosen for regulatory reasons rather than clinical ones Working notes rather than a conclusion. An honest uncertainty about comparators chosen for regulatory reasons…
|
2 | 27k | 14mo | |
|
Primary endpoint hierarchies and why order matters — one year on
On the subject in the title: Primary endpoint hierarchies and why order matters — one year on Working notes rather than a conclusion. A follow-up question about Primary endpoint hierarchies that I did not…
|
+56 | 61 | 37k | 11h |
|
Subgroup analyses: pre-specified versus discovered
Subgroup analyses: pre-specified versus discovered — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on subgroup analyses, and I…
|
2 | 27k | 1d | |
|
Subgroup analyses: pre-specified versus discovered — a second dataset
On the subject in the title: Subgroup analyses: pre-specified versus discovered — a second dataset Working notes rather than a conclusion. Posting a small dataset on Subgroup analyses. It is mine, it is…
|
+71 | 79 | 906 | 3mo |
Related topics — sharing the tags randomised trial, open label, intention to treat
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Journal club: FLOW and the renal composite, component by component
On the subject in the title: Journal club: FLOW and the renal composite, component by component Working notes rather than a conclusion. Reading FLOW ( N Engl J Med , 2024) for the population rather than the…
|
+84 | 91 | 18k | 2y |
|
Coming back to: What the published dose-response for semaglutide actually looks like above 2.4 mg
The question in the title: What the published dose-response for semaglutide actually looks like above 2.4 mg I will give what I have already checked below so nobody repeats it. I would like to know what…
|
+23 | 27 | 9.9k | 1mo |
|
Journal club: STEP 3 and the intensive behavioural therapy floor
Posting this under the heading it deserves: Journal club: STEP 3 and the intensive behavioural therapy floor Everything below is what sits behind that. Two things I would like separated before anyone answers…
|
+6 | 10 | 13k | 28d |
|
The most common factual error about semaglutide on the internet
On the subject in the title: The most common factual error about semaglutide on the internet Working notes rather than a conclusion. Putting the numbers in the first post, because a question about a compound…
|
2 | 49k | 2y | |
|
Semaglutide in people without diabetes: what the evidence base looks like
Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of semaglutide…
|
+2 | 6 | 18k | 17mo |